Abstract
Although the utilization of fenestrated endovascular repair for juxtarenal and pararenal aortic aneurysms has increased significantly over the past decade, there exists a paucity of data assessing long-term outcomes. As such, Sveinsson et al should be congratulated on their efforts in demonstrating high rates of procedural success and safety of the Zenith Fenestrated Device (Cook Medical Inc, Brisbane, Australia) for the treatment of juxtarenal aneurysms.1 Moreover, this study represents the best published data to date on long-term outcomes after fenestrated endovascular repair in the real-world clinical practice with comprehensive assessment of target vessel (TV) patency, and reintervention-free and overall survival among a patient population with near complete follow-up.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
